MLAB MESA LABORATORIES INC /CO/
Price Chart
Executive Summary
Mesa Labs reported Q4 FY2026 results with revenue of $63.7M (+2.6% YoY), slightly above the $60.9M consensus, but GAAP EPS was a loss of $(0.75), a massive miss vs the $2.55 consensus. The GAAP loss was driven by $6.7M in CEO transition costs (including $3.7M accelerated stock comp). On an adjusted basis (AOI excluding unusual items), EPS was $3.30, well above the Street consensus of $1.53. The BPD division saw a 29.9% organic revenue decline due to export controls and commercial execution issues, while SDC grew 17.7% aided by backlog clearance. No formal guidance was provided; management expects to issue guidance with H1 results. The stock will likely trade on the strong adjusted earnings and debt paydown, offset by BPD weakness and lack of near-term visibility.
Key Financial Metrics
Actionable Insight
The strong adjusted earnings and margin expansion (AOI margin 28.7%) should support the stock near-term, but the BPD division's 29.9% organic decline and lack of formal guidance create uncertainty. Watch for export control developments and the H1 FY2027 guidance update for a clearer trajectory. The net leverage reduction to 2.11x is a positive credit signal.
Key Facts
- Q4 revenue $63.7M, +2.6% YoY, above $60.9M consensus
- GAAP EPS $(0.75) vs consensus $2.55 — miss driven by $6.7M CEO transition costs
- Adjusted EPS (AOI ex unusual items) $3.30, well above Street consensus of $1.53
- AOI ex unusual items margin 28.7%, up from 19.7% a year ago
- BPD organic revenue declined 29.9% due to export controls and commercial execution
- SDC organic revenue grew 17.7%, aided by ~$2.0M backlog clearance
- Repaid $14.7M of debt; net leverage ratio reduced to 2.11x from 2.62x in Q3
- No formal FY2027 guidance provided; management expects to issue with H1 results
- Free cash flow for FY2026 was $39.6M, down from $42.6M in FY2025
Financial Impact
Revenue beat by ~$2.8M (4.6%) vs consensus; GAAP EPS miss of $(3.30) vs consensus; adjusted EPS beat by ~$1.77 vs Street consensus of $1.53
Risk Factors
- BPD division revenue decline of 29.9% due to export controls and commercial execution issues
- No formal FY2027 guidance provided; visibility limited until H1 results
- CEO transition costs ($2.99M in Q4) may recur in early FY2027
- Core organic revenue growth was negative (0.6%) in Q4, indicating underlying weakness
- China CG revenue continued to contract (34% YoY decline in Q4)
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000724004-26-000039 |
| Document: mlab20260526_8k.htm | 0000724004-26-000039 |
| Document: 0000724004-26-000039-index-headers.html | 0000724004-26-000039 |
| Document: 0000724004-26-000039-index.html | 0000724004-26-000039 |
| Document: 0000724004-26-000039.txt | 0000724004-26-000039 |
| 8-K Data (Synthetic) | 0000724004-26-000039 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
16d ago
|
8-K
| $90.66 $104.38 | ▲ +15.13% | ▲ +14.67% | $105.48 (+16.35%) |
|
May 5, 2026
5w ago
|
Press Release
| $103.85 $102.89 | ▼ −0.92% | ▼ −2.91% | $105.48 (+1.57%) |
|
Mar 10, 2026
13w ago
|
Insider Cluster
| $73.23 $81.69 | ▲ +11.55% | ▲ +12.46% | $105.48 (+44.04%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $73.23 $81.69 | ▲ +11.55% | ▲ +12.46% | $105.48 (+44.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access